Insider Selling: Surrozen, Inc. (NASDAQ:SRZN) VP Sells $14,642.91 in Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 843 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $17.37, for a total value of $14,642.91. Following the completion of the sale, the vice president now owns 13,345 shares of the company’s stock, valued at approximately $231,802.65. This trade represents a 5.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Surrozen Price Performance

SRZN stock opened at $12.81 on Thursday. The company’s 50-day moving average price is $11.11 and its two-hundred day moving average price is $9.97. Surrozen, Inc. has a 12 month low of $6.00 and a 12 month high of $18.17.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($2.77) by $2.33. The firm had revenue of $10.00 million for the quarter. On average, sell-side analysts expect that Surrozen, Inc. will post -7.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Guggenheim upgraded Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price for the company in a research report on Friday, January 3rd.

Institutional Trading of Surrozen

Institutional investors and hedge funds have recently modified their holdings of the business. CVI Holdings LLC acquired a new position in Surrozen during the second quarter worth about $711,000. Stonepine Capital Management LLC bought a new stake in shares of Surrozen during the 2nd quarter valued at approximately $724,000. Nantahala Capital Management LLC acquired a new position in Surrozen during the 2nd quarter worth approximately $2,050,000. Finally, Armistice Capital LLC acquired a new position in Surrozen during the 2nd quarter worth approximately $2,080,000. 66.57% of the stock is currently owned by institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.